Table 1.
Baseline patient characteristics.
| Whole cohort (n = 3,276) | |
|---|---|
| Age (years) | 63 (54–71) |
| Female | 1,261 (38.5) |
| Dialysis duration (years) | 8.3 (3.7–14.3) |
| Serum albumin (mg/dL) | 3.8 (3.5–4.0) |
| Cardiovascular disease | 1,965 (60.0) |
| Hypertension | 2,613 (79.8) |
| Diabetes | 1,026 (31.3) |
| Cancer | 165 (5.0) |
| Single-pool Kt/V | 1.41 (1.23–1.58) |
| Body mass index (kg/m2) | 20.9 (19.0–23.3) |
| Corrected calcium (mg/dL) | 9.7 (9.1–10.4) |
| Corrected calcium 8.4–10 mg/dLa | 1,829 (55.8) |
| Phosphorus (mg/dL) | 5.5 (4.6–6.3) |
| Phosphorus 3.5–6 mg/dLa | 2,073 (63.3) |
| Intact PTH (pg/mL) | 265 (195–392) |
| Intact PTH 60–240 pg/mLa | 1,282 (39.1) |
| Cinacalcet use during the follow-up | 1,384 (42.3) |
| Intravenous Vitamin D use at baseline | 1,596 (48.7) |
| Phosphate binder use at baseline | 2,995 (85.3) |
Values are presented as median (range) or n (%).
aThe targets of bone mineral markers used here were those outlined in the Japanese clinical guidelines.
PTH, parathyroid hormone.